The global acute repetitive seizures market accounted for USD 3.00 billion in 2023 and is expected to reach USD 10.94 billion by 2034 with a CAGR of 12.47% during the forecast period 2024-2034. The market will rise as a result of factors such as the rising prevalence of neurological disorders, increased awareness of ARS, the need for early intervention, a robust pipeline of new therapies and R&D initiatives, technological advancements, and a focus on patient-centered care.
Research and development of novel drugs tailored to treat ARS is a dynamic endeavor for pharmaceutical companies. The ARS market has a bright future thanks to this strong pipeline of possible treatments, which includes NRL-1, USL-261, and AZ-002. For instance, in October 2022, Sunovion Pharmaceuticals Inc. reported encouraging outcomes from a Phase 2b clinical trial using Sunosi (solriamfetol) as an adjuvant treatment for people with uncontrolled partial-onset seizures.
By product, the USL-261 segment accounted for the highest revenue-grossing segment in the global acute repetitive seizures market in 2023 owing to the high efficacy, favorable safety profile, and widespread adoption among patients with refractory epilepsy. For instance, in September 2022, Neurelis, Inc. reported encouraging outcomes from a Phase 2a clinical trial assessing THR-400 for the treatment of acute repeated seizures. Additionally, the AZ-002 segment is predicted to grow at the fastest CAGR during the forecast period owing to the novel mechanism of action, promising clinical trial results, and increasing research investments in the development of this emerging treatment option for acute repetitive seizures.
By end-user, the hospitals & clinics segment accounted for the highest revenue-grossing segment in the global acute repetitive seizures market in 2023 owing to the increased patient admissions for diagnosis, treatment, and management of acute repetitive seizures, coupled with advanced medical facilities and specialized expertise available in hospital settings. For instance, in January 2022, UCB acquired Midazolam nasal spray (USL-61) from Proximagen to broaden its epilepsy portfolio. Additionally, the ambulatory settings segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising preference for outpatient care, advancements in telemedicine and remote monitoring technologies, and efforts to reduce healthcare costs by shifting patient care from traditional hospital settings to ambulatory settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of epilepsy, well-established healthcare infrastructure, strong regulatory framework supporting drug development, and increasing adoption of advanced treatment modalities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about epilepsy, improving healthcare infrastructure, increasing access to treatment, and growing investments in research and development in the region. For instance, in March 2022, Biogen collaborated with Eisai on aducanumab (ADUHELM) for Alzheimer's disease.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Research and development of novel drugs tailored to treat ARS is a dynamic endeavor for pharmaceutical companies. The ARS market has a bright future thanks to this strong pipeline of possible treatments, which includes NRL-1, USL-261, and AZ-002. For instance, in October 2022, Sunovion Pharmaceuticals Inc. reported encouraging outcomes from a Phase 2b clinical trial using Sunosi (solriamfetol) as an adjuvant treatment for people with uncontrolled partial-onset seizures.
By product, the USL-261 segment accounted for the highest revenue-grossing segment in the global acute repetitive seizures market in 2023 owing to the high efficacy, favorable safety profile, and widespread adoption among patients with refractory epilepsy. For instance, in September 2022, Neurelis, Inc. reported encouraging outcomes from a Phase 2a clinical trial assessing THR-400 for the treatment of acute repeated seizures. Additionally, the AZ-002 segment is predicted to grow at the fastest CAGR during the forecast period owing to the novel mechanism of action, promising clinical trial results, and increasing research investments in the development of this emerging treatment option for acute repetitive seizures.
By end-user, the hospitals & clinics segment accounted for the highest revenue-grossing segment in the global acute repetitive seizures market in 2023 owing to the increased patient admissions for diagnosis, treatment, and management of acute repetitive seizures, coupled with advanced medical facilities and specialized expertise available in hospital settings. For instance, in January 2022, UCB acquired Midazolam nasal spray (USL-61) from Proximagen to broaden its epilepsy portfolio. Additionally, the ambulatory settings segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising preference for outpatient care, advancements in telemedicine and remote monitoring technologies, and efforts to reduce healthcare costs by shifting patient care from traditional hospital settings to ambulatory settings.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of epilepsy, well-established healthcare infrastructure, strong regulatory framework supporting drug development, and increasing adoption of advanced treatment modalities in the region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rising awareness about epilepsy, improving healthcare infrastructure, increasing access to treatment, and growing investments in research and development in the region. For instance, in March 2022, Biogen collaborated with Eisai on aducanumab (ADUHELM) for Alzheimer's disease.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Product, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Acute Repetitive Seizures Market Report 2023 - 2034
Acute Repetitive Seizures Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- USL-261
- NRL-1
- AZ-002
- Diastat Rectal Gel
- Others
Acute Repetitive Seizures Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals & Clinics
- Ambulatory Settings
- Others
Acute Repetitive Seizures Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Acute Repetitive Seizures Market: Product Estimates & Trend Analysis
8. Acute Repetitive Seizures Market: End-User Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Acute Repetitive Seizures Market
11. Europe Acute Repetitive Seizures Market
12. Asia Pacific Acute Repetitive Seizures Market
13. Latin America Acute Repetitive Seizures Market
14. MEA Acute Repetitive Seizures Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- UCB Pharma
- Eisai Co. Ltd.
- Novartis AG
- Pfizer Inc.
- GW Pharmaceuticals
- Sunovion Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Marinus Pharmaceuticals
- H. Lundbeck A/S
- Neurelis Inc.
- SK Biopharmaceuticals Co. Ltd.
- Zogenix Inc.
- Biogen
- Ovid Therapeutics Inc.
- Sage Therapeutics.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3 Billion |
| Forecasted Market Value ( USD | $ 10.94 Billion |
| Compound Annual Growth Rate | 12.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
